Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Plasma Rich in Growth Factors in Corneal Endothelial Transplantation

NCT06261346 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of the study is to determine the safety and efficacy of brief intraoperative corneal endothelial graft incubation in plasma rich in growth factors (PRGF) for reducing postoperative endothelial cell loss.

Interventions

  • PROCEDURE Endothelial keratoplasty
  • BIOLOGICAL PRGF

Study Locations (2)

Florida

  • Bascom Palmer Eye Institute — Miami

Indiana

  • Price Vision Group — Indianapolis

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-07-12
Est. Completion 2026-10-30
Phase NA

Sponsor

University of Miami

667 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06261346

The ClinicalTrials.gov registry entry for NCT06261346 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 667 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Fuchs' Endothelial Dystrophy appearing as the primary indexed condition, and to 2 interventions — of which Endothelial keratoplasty is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06261346 reports 2 study locations spanning 2 distinct geographic areas — top geographies include Florida, Indiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06261346 about?

NCT06261346 is a clinical study titled "Plasma Rich in Growth Factors in Corneal Endothelial Transplantation". The purpose of the study is to determine the safety and efficacy of brief intraoperative corneal endothelial graft incubation in plasma rich in growth factors (PRGF) for reducing postoperative endothelial cell loss.

What is the current status of trial NCT06261346?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2024-07-12. Estimated completion is 2026-10-30.

What conditions does trial NCT06261346 study?

This clinical trial studies the following conditions: Fuchs' Endothelial Dystrophy, Corneal Edema. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06261346?

The interventions under investigation include: Endothelial keratoplasty (PROCEDURE), PRGF (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06261346?

This trial is sponsored by University of Miami, which has 667 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06261346 being conducted?

This trial has 2 study locations across Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial